Language

Chinese English

Home page

Forum Agenda

CNS Novel Drug R&D Session

Stay tuned

Development of New Molecular Entity Drugs for Antipsychotic Indications
Tian Jingwei: Executive Vice President of R&D, Luye Pharma Group; Dean, School of Pharmacy, Yantai University

Medical Use and Market Prospects of Modified Psychedelics in Light of the FDA's New Guidance and Trump's Executive Order
Shen Huajiong: Founder & CEO, NeuShen Therapeutics

“PRODEGRE ATLAS – A Protein Degradation Innovation Platform to Enable Breakthrough Therapies for CNS Disorders”
Tan Shen: Co-Founder & CEO, Pridarray Biotech

Universal iPSC-Derived Cell Therapy for Brain Injury-Related Disorders
Fan Jing: Founder & CEO, Hopstem Biotechnology

Development of a Novel Small Molecule Drug for Stroke
Chen Rong: Deputy General Manager, Ningen Pharma

Development and Global Pathway of QP001 Injection
Yu Sen: VP, Qingpu Biopharma

Preliminary Validation of iPSC-Based Therapies for CNS Diseases Derived from the SISBAR Core Technology Platform
Wu Lanlin: CEO, Yuesai Biotechnology

Expanding the Extrabepatic Application of Small Nucleic Acid Drugs – R&D Progress in CNS Diseases
Gao Shan: Senior Vice President & Chief Scientist, Ribo Life Science

Research Progress of Cyclopolysaccharide Analog AMCDx Platform in CNS Diseases
Qi Youmao: Chairman, Aomu Pharma; Head of Academician Workstation; Chief Scientist

The Path to Clinical Translation of Innovative Biopharmaceuticals – Opportunities, Challenges, and Collaboration
Si Tianmei: Vice President, Peking University Sixth Hospital; Deputy Director, Institute of Mental Health

Frontier Technology in Innovative Drug Development
Isaac Cheng: VP of Research, Suntec Medical

Discovery and Development of a Novel Dual-Target, Non-Opioid Potent Analgesic
Sheng Xijun: Director, Innovation Research Center, Yichang Humanwell

Panel Discussion – The Future of CNS Drug R&D
Hei Yongjiang: Founder, Huisibo Biotech
Fang Qun: Chief Scientific Officer, Yisi Biotech; Head, Brain Science Innovation R&D Center
Li Qun: General Manager, Saipute
Wang Bingjie: CBO, Sunshine Angene Biotech

Follow or Contact Us

Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.

Public Account QR Code

Registration QR Code

Conference Service Hotline

+86 010 8363 4290

© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.